Lonza Group (LZAGY) & Indivior (INVVY) Financial Survey

Lonza Group (OTCMKTS: LZAGY) and Indivior (OTCMKTS:INVVY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a summary of current ratings for Lonza Group and Indivior, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lonza Group 0 0 1 0 3.00
Indivior 0 0 0 0 N/A


This table compares Lonza Group and Indivior’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lonza Group N/A N/A N/A
Indivior 5.31% -89.83% 21.92%

Valuation and Earnings

This table compares Lonza Group and Indivior’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lonza Group $5.19 billion 3.51 $737.83 million $0.85 28.77
Indivior $1.09 billion 4.05 $58.00 million $1.80 16.89

Lonza Group has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Lonza Group, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.2% of Lonza Group shares are owned by institutional investors. Comparatively, 0.0% of Indivior shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Lonza Group has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Indivior has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

About Lonza Group

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients for life-saving medicines; manufactures commercial bulk drug substance of monoclonal antibodies and recombinant proteins from mammalian cell cultures; and chemical contract manufacturing services, such as microbials, peptides, and small molecules. It also offers process development and manufacturing services for cell therapy, viral therapy, and antibody drug conjugates; cell culture, transfection, and molecular biology tools for life-science research; media to produce therapeutics; endotoxin detection assays; and products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer, and other disease research areas. This segment serves customers in academic and government institutions, and in biotech and pharmaceutical organizations. The Specialty Ingredients segment offers consumer care products comprising actives for antidandruff shampoos; cosmetic ingredients; vitamin B3 compounds; and L-Carnitine and microbial control solutions, including disinfectants and sanitizers that protect from dangerous and unwanted microbes. This segment also provides active ingredients for mollusk control; custom agricultural manufacturing services to enhance crop yields and food quality; preservatives and additives for crop protection formulations, as well as animal feed additives; chemical technologies; sanitizers and other treatment chemicals for pools, spas, and water parks, as well as for the treatment of surface waters and water for drinking, agriculture, irrigation, food processing, and industrial applications; and offers feeder systems and controllers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.

About Indivior

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It markets and promotes SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company was incorporated in 2014 and is headquartered in Richmond, Virginia.

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply